Regulatory disincentives for developing antibiotics for common indications

Area of Science:

• Infectious Diseases
• Pharmacology
• Regulatory Science

Background:

• Community-acquired respiratory tract infections (CARTIs) are highly prevalent in pediatric and adult populations.
• Antibiotics for CARTIs have historically been profitable, yet new drug development has significantly declined over the last decade.
• There is an ongoing, unmet need for novel therapeutic agents to combat these common infections.

Purpose of the Study:

• To investigate regulatory guidelines that may contribute to the lack of new antibiotic development for CARTIs.
• To identify and propose practical solutions to overcome these developmental barriers.

Main Methods:

• This is a review article.
• Analysis of existing regulatory frameworks and guidelines related to antibiotic development.
• Synthesis of information to propose actionable strategies.

Main Results:

• Identified specific regulatory aspects potentially hindering antibiotic innovation.
• Outlined several practical approaches to address these challenges.

Conclusions:

• Regulatory guidelines may inadvertently stifle the development of new antibiotics for common respiratory infections.
• Addressing these regulatory issues is crucial to foster innovation and meet the evolving need for effective CARTI treatments.